This message was sent to ##Email##
|
|
|
SCAI
Interventional/Invasive Cardiology's foremost peer-reviewed journal, Catheterization and Cardiovascular Interventions (CCI) is the official publication of SCAI.
Current issue: Volume 87, Issue 7 (1 June 2016)

By: Gregory J. Dehmer, MD, MSCAI
SCAI has again collaborated with the American College of Cardiology, the American Heart Association, the Society of Thoracic Surgery and other organizations to develop appropriate use criteria (AUC) for coronary artery revascularization. The first such document was published in 2009, an update was published in 2012 and recently the latest version of the AUC was released. For the latest version, two documents were developed, one specific for acute coronary syndromes (ACS) and the other specific for stable ischemic heart disease (SIHD)1, 2.
Promoted by
|
|
|
 |
SCAI
SCAI is excited to welcome Kaysha Johnston to our team! In this role, Kaysha will provide graphic design, copywriting, advertising, print production, web and video support for SCAI communications, marketing, membership, and educational activities.
Kaysha is a native Northern Virginian and now lives in Washington, D.C. with her husband Michael, her daughter Vivienne, and her dog Zoe. She went to George Mason University where she majored in French and International Relations and then George Washington University where she received her Master's in Publishing.
Welcome, Kaysha!
SCAI
The Proposed Rule addresses participation requirements for 2018 and future years under the Merit-Based Incentive Payment System (MIPS) and the Advanced Alternative Payment Model (Advanced APM) pathways created by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Under the proposal, CMS will continue to treat the 2018 performance year as another transition year of QPP and maintain program flexibility. Based on 2018 performance, clinicians and groups will be eligible to receive up to + / - 5 percent in bonuses or penalties on Medicare Part B services provided in 2020 under MIPS. Qualifying participants in an Advanced APM will be eligible to receive a five percent lump sum bonus. Comments are due on August 21, 2017.
Cardiovascular Business
An experimental transcatheter device by Canada-based Neovasc, used to treat mitral regurgitation, was shown to be effective in treating a patient with several severe heart conditions. The Tiara, still an investigational device, was shown in a presentation by Shmuel Banai, M.D., the director of interventional cardiology at the Tel Aviv Medical Center and Neovasc’s medical director, at this year’s Transcatheter Valve Therapies conference.
READ MORE
 |
|
Chiesi USA, Inc., headquartered in Cary, NC, is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Visit www.chiesiusa.com for more information.
|
|
TCTMD
A “minimalist” approach to transcatheter aortic valve replacement (TAVR) can be safely done without an increased risk of patient morbidity or mortality at experienced hospitals, according to several presentations at TVT 2017.
In a session devoted to simplified TAVR pathways, including some single-center results, researchers outlined the many reasons for adopting protocols that see patients treated without general anesthesia and moved from the catheterization laboratory directly to the telemetry floor and discharged the next day.
READ MORE
Healio
Interventional treatment of congenital heart disease has progressed during the past 40 years and has led to improved survival rates, although survival remains lower than the general population, according to a study in the Journal of the American College of Cardiology. Signe H. Larsen, M.D., Ph.D., of the department of cardiology at Aarhus University Hospital in Denmark, and colleagues reviewed data from 9,372 children younger than 18 years from Denmark who were treated for congenital heart disease from 1977 to 2015.
READ MORE
Cardiovascular Business
A new mitral regurgitation (MR) therapy designed to treat patients with structural heart disease was shown to be a safer treatment option than other transcatheter mitral valve replacement (TMVR).
The valve, designed by 4C Medical Technologies in Brooklyn Park, Minnesota, is the first MR therapy that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology.
READ MORE
TCTMD
A worldwide recall has been initiated of certain intra-aortic balloon pump (IABP) systems to address potential electrical test failures.
READ MORE
Date |
Event |
Location |
July 21-22, 2017 |
Complex Interventional Cardiovascular Therapy A Case Based Workshop- 11th Annual Meeting
|
San Francisco, CA
|
July 28-29, 2017 |
SDCI: San Diego Cardiovascular Interventions, Robotics and CHIP
|
La Jolla, CA
|
August 3-5, 2017 |
Cardiovascular Innovations 2017 |
Denver, CO
|
August 18-20, 2017 |
ACC/SCAI Premier Interventional Cardiology Overview and Board Preparatory Course |
Washington, DC
|
Dec. 9-12, 2017 |
SCAI 2017 Fall Fellows Courses |
Las Vegas, NV
|
Job Title |
Employer |
Location |
Physician - Cardiology-Interventional |
Cejka Search |
Flagstaff, Arizona
|
Interventional Cardiologist |
Central PA Cardiology |
Central Pennsylvania, Pennsylvania
|
Clinical Nurse-Registered Nurse Adult Critical Care |
Yale New Haven Hospital |
New Haven, Connecticut
|
For a complete list of job postings, click here.
To post your resume, click here.
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
|
|
|
|
|
 7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|